Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
C Weimar, J Beyer-Westendorf, F O Bohmann, G Hahn, S Halimeh, S Holzhauer, C Kalka, M Knoflach, H-C Koennecke, F Masuhr, M-L Mono, U Nowak-Göttl, E Scherret, M Schlamann, B Linnemann
Over the last years, new evidence has accumulated on multiple aspects of diagnosis and management of cerebral venous and dural sinus thrombosis (CVT) including identification of new risk factors, studies on interventional treatment as well as treatment with direct oral anticoagulants. Based on the GRADE questions of the European Stroke Organization guideline on this topic, the new German guideline on CVT is a consensus between expert representatives of Austria, Germany and Switzerland. New recommendations include:• CVT occurring in the first weeks after SARS-CoV-2 vaccination with vector vaccines may be associated with severe thrombocytopenia, indicating the presence of a prothrombotic immunogenic cause (Vaccine-induced immune thrombotic thrombocytopenia; VITT)...
April 19, 2024: Neurological research and practice
#2
Daniel Edward Horner, Sarah Davis, Abdullah Pandor, Helen Shulver, Steve Goodacre, Daniel Hind, Saleema Rex, Michael Gillett, Matthew Bursnall, Xavier Griffin, Mark Holland, Beverley Jane Hunt, Kerstin de Wit, Shan Bennett, Robin Pierce-Williams
BACKGROUND: Pharmacological prophylaxis during hospital admission can reduce the risk of acquired blood clots (venous thromboembolism) but may cause complications, such as bleeding. Using a risk assessment model to predict the risk of blood clots could facilitate selection of patients for prophylaxis and optimise the balance of benefits, risks and costs. OBJECTIVES: We aimed to identify validated risk assessment models and estimate their prognostic accuracy, evaluate the cost-effectiveness of different strategies for selecting hospitalised patients for prophylaxis, assess the feasibility of using efficient research methods and estimate key parameters for future research...
April 2024: Health Technology Assessment: HTA
#3
REVIEW
Charalampos Charalampous, Darshi Shah, Shaji Kumar, Rajshekhar Chakraborty
Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed patients and varying frequency in the relapsed/refractory setting. Accurate VTE risk assessment and personalized thromboprophylaxis strategies are important parts of supportive care in myeloma. There are three validated risk assessment models for prediction of VTE risk in newly diagnosed myeloma-SAVED, IMPEDE-VTE, and PRISM. In this review, we delve into the practical applications of VTE risk prediction models in the context of current therapies...
April 17, 2024: Annals of Hematology
#4
JOURNAL ARTICLE
Bryce E Haac, Nathan N O'Hara, Elliott R Haut, Theodore T Manson, Gerard P Slobogean, Robert V O'Toole, Deborah M Stein
OBJECTIVES: To determine venous thromboembolism (VTE) testing patterns in an orthopaedic trauma population and to evaluate for differences in VTE surveillance by prophylaxis regimen through a secondary analysis of the ADAPT trial. DESIGN: Prospective randomized trial. SETTING: Level I trauma center. PATIENTS: Three hundred twenty-nine adult (18 years and older) trauma patients presenting with an operative extremity fracture proximal to the metatarsals/carpals or any pelvic or acetabular fracture requiring VTE prophylaxis...
June 2024: OTA international: the open access journal of orthopaedic trauma
#5
REVIEW
Emma L Klaserner, Kayla J Popova, Rikki-Leigh Gaudet
Venous thromboembolism (VTE), including both pulmonary embolism (PE) and deep vein thrombosis (DVT), is the leading cause of maternal death in developed countries. Pregnancy is associated with an increased risk of VTE due to physiologic changes during the obstetric period that promote a hypercoagulable state. Appropriate use of prophylactic anticoagulants can decrease the event rate of thrombus formation in at-risk patients. In the United States, there is not a validated risk-assessment tool for VTE in obstetric patients or a clear consensus on initiation and optimal dosing strategy for the prophylactic use of anticoagulants...
April 15, 2024: Journal of Pharmacy Practice
#6
JOURNAL ARTICLE
Benjamin Djulbegovic, Alice Boylan, Shelby J Kolo, Danielle Bowen Scheurer, Sydney Anuskiewicz, Flora Khaledi, Kimberley Youkhana, Sarah Madgwick, Neema Maharjan, Iztok Hozo
Current hospital VTE (venous thromboembolism) prophylaxis for medical patients has been characterized by both underuse and, increasingly, overuse. The American Society of Hematology (ASH) has endorsed the use of risk assessment models (RAM) as an approach to individualize VTE prophylaxis as a way of balancing overuse (excessive risk of bleeding) and underuse (risk of avoidable VTE). ASH has endorsed IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) risk assessment models - the only RAM to assess short-term bleeding and VTE risk in acutely ill medical inpatients...
April 15, 2024: Blood Advances
#7
JOURNAL ARTICLE
Tolulope B Fatokun, Sarah E Swartz, Ahmed Ebeid, Sophia A Cordes, Alexis C Gimovsky, Andrew D Sparks, Richard L Amdur, Homa K Ahmadzia
Venous thromboembolism (VTE) is a leading cause of maternal mortality. Obesity and cesarean delivery are established risk factors for pregnancy-related VTE. We identified additional risk factors among patients with obesity who underwent a cesarean delivery to identify those who need VTE prophylaxis. We conducted a secondary analysis of data from the Maternal-Fetal Medicine Units Network (MFMU) Cesarean Registry Database using a case-control design. Cases were identified as women with obesity having a pre-pregnancy body mass index of >30 kg/m2 , who underwent cesarean delivery and subsequently developed deep venous thrombosis (DVT) or pulmonary embolism (PE)...
2024: Clinical and Applied Thrombosis/hemostasis
#8
JOURNAL ARTICLE
Amit Joshi, Nishchal Rijal, Subash Gurung, Bibek Basukala, Rajiv Sharma, Rohit Bista, Nagmani Singh, Ishor Pradhan
BACKGROUND: Although rare, deep vein thrombosis is a potentially life-threatening complication of knee arthroscopy. There are scanty literature analysing deep vein thrombosis after arthroscopy in Nepal. This study aimed to identify the prevalence of deep vein thrombosis in patients undergoing knee arthroscopy without chemoprophylaxis postoperatively at 2 weeks and 6 weeks, respectively. The study also aimed to estimate the risk of deep vein thrombosis in these patients by using Caprini Risk Assessment Model...
March 31, 2024: Journal of Nepal Health Research Council
#9
JOURNAL ARTICLE
Asanthi M Ratnasekera, Sirivan S Seng, Daniel Kim, Wenyan Ji, Christina L Jacovides, Elinore J Kaufman, Hannah M Sadek, Lindsey L Perea, Christina Monaco Poloni, Ilya Shnaydman, Alexandra Jeongyoon Lee, Victoria Sharp, Angela Miciura, Eric Trevizo, Martin G Rosenthal, Lawrence Lottenberg, William Zhao, Alicia Keininger, Michele Hunt, John Cull, Chassidy Balentine, Tanya Egodage, Aleem T Mohamed, Michelle Kincaid, Stephanie Doris, Robert Cotterman, Sara Seegert, Lewis E Jacobson, Jamie Williams, Melissa Moncrief, Brandi Palmer, Caleb Mentzer, Nichole Tackett, Tjasa Hranjec, Thomas Dougherty, Shawna Morrissey, Lauren Donatelli-Seyler, Amy Rushing, Leah C Tatebe, Tiffany J Nevill, Michel B Aboutanos, David Hamilton, Diane Redmond, Daniel C Cullinane, Carolyne Falank, Mark McMellen, Chris Duran, Jennifer Daniels, Shana Ballow, Kevin M Schuster, Paula Ferrada
BACKGROUND: In patients with severe traumatic brain injury (TBI), clinicians must balance preventing venous thromboembolism (VTE) with the risk of intracranial hemorrhagic expansion (ICHE). We hypothesized that low molecular weight heparin (LMWH) would not increase risk of ICHE or VTE as compared to unfractionated heparin (UH) in patients with severe TBI. METHODS: Patients ≥ 18 years of age with isolated severe TBI (AIS ≥ 3), admitted to 24 level I and II trauma centers between January 1, 2014 to December 31, 2020 and who received subcutaneous UH and LMWH injections for chemical venous thromboembolism prophylaxis (VTEP) were included...
April 9, 2024: Injury
#10
JOURNAL ARTICLE
James French, Keslin Greenwood
No abstract text is available yet for this article.
November 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
#11
JOURNAL ARTICLE
Masato Saitoh, Takemi Kudo, Takao Watanabe
BACKGROUND: Among venous thromboembolism, pulmonary thromboembolism (PTE) is one of the most serious postoperative complications. Deep venous thrombosis (DVT) is the main cause. Considering the unknown prevalence of DVT and PTE in the postoperative period of cardiovascular surgery in Japan, we investigated the incidence in consecutive patients who underwent cardiovascular surgery. METHODS: A total of 225 patients who underwent cardiovascular surgery at four hospitals consented to participate in the study...
April 13, 2024: Asian Cardiovascular & Thoracic Annals
#12
JOURNAL ARTICLE
Muhan Hu, Christina T Blanchard, Angela R Seasely, Michelle Lu, Jeff M Szychowski, Brian Casey, Alan T Tita, George Saade, Akila Subramaniam
OBJECTIVE: We evaluated if venous thromboembolism (VTE) prophylaxis in the inpatient antepartum period was associated with wound hematomas, VTE occurrence, and other adverse outcomes. STUDY DESIGN: This study is a secondary analysis of a retrospective cohort of patients who delivered at University of Alabama at Birmingham (UAB). Patients receiving outpatient anticoagulation (AC) were excluded. We grouped patients into those who received inpatient antepartum prophylactic AC and those who did not...
April 12, 2024: American Journal of Perinatology
#13
JOURNAL ARTICLE
James Xu, Elad Neeman, Khanh K Thai, Pranita Mishra, David Schlessinger, Heather Clancy, Laura Myers, Nareg Roubinian, Vincent Liu, Raymond Liu
BACKGROUND: Hospital-acquired venous thromboembolism (HA VTE) is a preventable complication in hospitalized patients. OBJECTIVE: We aimed to examine the use of pharmacologic prophylaxis (pPPX) and compare two risk assessment methods for HA VTE: a retrospective electronic Padua Score (ePaduaKP) and admitting clinician's choice of risk within the admission orderset (low, moderate, or high). DESIGN, SETTINGS AND PARTICIPANTS: We retrospectively analyzed prophylaxis orders for adult medical admissions (2013-2019) at Kaiser Permanente Northern California, excluding surgical and ICU patients...
April 12, 2024: Journal of Hospital Medicine: An Official Publication of the Society of Hospital Medicine
#14
JOURNAL ARTICLE
István Zsenák, Alexandra Makai, Gabriella Kiss, Béla Faludi, Alexandra Straub, Brigitta Szilágyi, Anita Velényi, Melinda Járomi
INTRODUCTION: Studies have shown that using mechanical thromboembolic prophylaxis methods speeds up venous flow and decreases stasis. These studies examine the post-intervention period of 1-10 min. The length of the effect of procedures to raise venous flow velocity cannot be determined by clinical trials. To apply mathematical techniques to estimate how long mechanical thromboembolism prophylaxis procedures will increase venous flow rate. METHODS: In the survey, we examined 25 persons (poststroke patients), with an average age of 57...
2024: Frontiers in Physiology
#15
JOURNAL ARTICLE
Danielle Morgan, Jinjoo Kang, Chana Levine, Suchitra Acharya
OBJECTIVES: Enoxaparin for the prevention of venous thromboembolism (VTE) in pediatric patients is -typically dosed twice a day. The use of once-daily dosing like that used in adult patients is limited because of a lack of safety and efficacy data. The aim of this study was to evaluate the safety and efficacy of -once-daily versus twice-daily dosing of enoxaparin for pediatric VTE prophylaxis based on incidence of thrombotic and bleeding events. METHODS: This was a 3-year retrospective chart review of enoxaparin received for VTE prophylaxis at -Cohen Children's Medical Center, New Hyde Park, NY...
April 2024: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
#16
Laura Bounaix, Verena Schroeder, Pierre Fontana, Alessandro Casini
BACKGROUND: Thrombotic events in congenital factor (F)XIII deficiency are extremely rare. To our knowledge, we describe the first case of severe congenital FXIII deficiency associated with recurrent venous thrombotic events. KEY CLINICIAN QUESTION: How to deal with anticoagulation treatment in patients with severe FXIII deficiency? CLINICAL APPROACH: The patient was treated with rivaroxaban and plasma-derived FXIII substitution therapy as prophylaxis without bleeding complications...
February 2024: Research and Practice in Thrombosis and Haemostasis
#17
JOURNAL ARTICLE
Kunapa Iam-Arunthai, Supat Chamnanchanunt, Pravinwan Thungthong, Poj Intalapaporn, Chajchawan Nakhahes, Tawatchai Suwanban, Ponlapat Rojnuckarin
Background: Internationally established guidelines mention pharmacological prophylaxis for all hospitalized COVID-19 patients. However, there are concerns regarding the efficacy and safety of anticoagulants. This study investigated the associations between thrombosis/bleeding risk scores and clinical outcomes. Methods: We conducted a retrospective review of adult patients admitted to two hospitals between 2021 and 2022. We analyzed clinical data, laboratory results, low molecular weight heparin (LMWH) use, thrombosis, bleeding, and 30-day survival...
March 1, 2024: Journal of Clinical Medicine
#18
REVIEW
Giorgio Maraziti, Maria Giulia Mosconi, Maurizio Paciaroni
BACKGROUND: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), are frequent complications in patients with intracerebral hemorrhage (ICH). Various prophylactic strategies have been employed to mitigate this risk, such as heparin, intermittent pneumatic compression (IPC), and graduated compression stockings (GCS). The optimal thromboembolic prophylaxis approach remains uncertain due to the lack of randomized controlled trials (RCTs) comparing all interventions...
April 9, 2024: International Journal of Stroke: Official Journal of the International Stroke Society
#19
REVIEW
Zhongbo Hu, Yogindra Persaud, Sanjay Ahuja
Asparaginase is essential in the initial management of acute lymphoblastic leukemia (ALL) but frequently leads to venous thromboembolism (VTE). Using anticoagulants for primary VTE prevention has been studied with no consensus. We conducted a systematic literature search in PubMed, Scopus, and Web of science and performed random-effect meta-analysis using Mantel-Haenszel method in RevMan 5.4 to analyze primary pharmacological thromboprophylaxis during asparaginase treatment in early-phase (induction, consolidation, or intensification phase) therapy in patients with ALL with all ages and followed with subgroup analysis by age...
April 5, 2024: Critical Reviews in Oncology/hematology
#20
JOURNAL ARTICLE
Casey R Erwin, Todd W Costantini, Andrea Krzyzaniak, Matthew J Martin, Jayraan Badiee, Alexandra S Rooney, Laura N Haines, Allison E Berndtson, Vishal Bansal, C Beth Sise, Richard Y Calvo, Michael J Sise
BACKGROUND: Conflicting evidence exists evaluating associations between cannabis (THC) and post-traumatic DVT. METHODS: Retrospective analysis (2014-2023) of patients ≥15yrs from two Level I trauma centers with robust VTE surveillance and prophylaxis protocols. Multivariable hierarchical regression assessed the association between THC and DVT risk. THC + patients were direct matched to other drug use categories on VTE risk markers and hospital length of stay...
March 26, 2024: American Journal of Surgery
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
